Form 4: Delcath Systems CEO Gerard Michel Acquires Stock Options

Delcath Systems CEO Gerard Michel was granted stock options to purchase 390,000 shares of common stock on February 7, 2025.

Summary

• On February 7, 2025, Gerard Michel, CEO of Delcath Systems, Inc., was granted stock options.
• These options allow him to purchase 390,000 shares of Delcath Systems common stock at an exercise price of $16.25 per share.
• The options vest monthly over three years, starting February 7, 2025, contingent upon continued employment.
• The options expire on February 7, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and aligns management with shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule of one-thirty-sixth per month is a fairly standard vesting schedule.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Delcath Systems, Gerard Michel, CEO, DCTH, equity incentive plan, vesting, Form 4